1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
High-Grade Glioma - Epidemiology Forecast - 2030

High-Grade Glioma - Epidemiology Forecast - 2030

  • July 2020
  • 100 pages
  • ID: 5921868
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘High-grade Glioma (HGG) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted High-grade Glioma (HGG) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

High-grade Glioma (HGG) Understanding
Highly malignant or high-grade gliomas (HGG) are tumors of the central nervous system (CNS), wherein high-grade means that the glioma is growing rapidly. They are solid tumors arising from transformed cells of the brain and/or the spinal cord. Since they directly originate from the CNS, they are also called primary CNS tumors, thereby differentiating them from malignant tumors of other organs that have spread (metastasized) to the CNS. HGG can occur in different parts of the central nervous system, and they can affect children of any age. The tumors most often originate in the supratentorial region of the brain and the brain stem; HGG originating from the supratentorial region are often called supratentorial HGG.
A glioma is a name for tumors of the glial cells, which are the supporting cells of the nervous system. Gliomas are classified based on the type of glial cells involved in the tumor as well as tumor’s genetic features. The World Health Organization (WHO) classification of CNS tumors is the most widely accepted system for classifying CNS tumors and was based on the histological characteristics of the tumor. As per the WHO classification system, grade III tumours (i.e. anaplastic astrocytoma, anaplastic oligoastrocytoma and anaplastic oligodendroglioma), grade IV tumours (i.e. Glioblastoma) and diffuse midline gliomas (DMG), H3K27M-mutant are considered to be high-grade gliomas (HGG).
HGGs account for approximately 15–20 % of CNS tumors in children and adolescents. They appear in all age groups, yet, children aged younger than three years are rarely affected. Each year, about 60–80 children and adolescents younger than 15 years are newly diagnosed with an HGG, which corresponds to an incidence rate of 5–10 new diagnoses/1, 000, 000 children/year. HGGs affect both boys and girls almost equally, and its symptoms vary depending on which area of the brain is affected.
The initial diagnostic procedures for a young patient presenting with a suspected CNS tumor at a childhood cancer center include another assessment of the patient’s history, a thorough physical/neurological exam and imaging diagnostic, such as magnetic resonance imaging (MRI). However, diagnostic procedures required for a definite and complete diagnosis of HGG involves:
• Imaging studies require a whole-brain scan, which can be done using MRI or CT. Both tests provide a very detailed image of the brain. Usually, a contrast dye is also given through a vein for the CT or MRI to visualize the brain better. However, a CT or MRI cannot determine for sure if a mass is a brain tumor.
• The only way to determine the type of tumor with certainty is for a neurosurgeon to remove a piece of the tumor during surgery (resection), which can then be studied under a microscope.
• A biopsy may be done without a larger surgery; this approach is preferred if the tumor is located within a critical area of the brain or if the patient is too sick for surgery. In these circumstances, a procedure called a stereotactic needle biopsy is used to take a sample of the tumor by inserting a needle through the skull into the brain itself.
Treatment for HGG usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is usually one of the most important aspects of treatment, although rarely used alone. Since HGGs develop very rapidly, they are often difficult to remove in their entirety. Therefore, surgery is performed to achieve a maximum safe resection - removing as much of the tumor as possible while preserving the patient’s brain function and sparing healthy tissues. Residual cancer cells can be targeted with additional treatments, such as chemotherapy or radiation therapy, after surgery. Radiation therapy and chemotherapy usually follow surgery once the diagnosis or name of the tumor is determined. These treatments are called adjuvant treatments. Because this multispeciality approach can cause several side effects, steroids are often provided as another essential part of HGG treatment, used to help alleviate the side effects of other therapies.

<>High-grade Glioma (HGG) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of High-grade Glioma (HGG), Total Incident Population of Diffuse Midline Glioma (DMG), Total Incident Population of Diffuse Midline Glioma With H3K27 Mutation and Gender-specific Incidence of High-grade Glioma (HGG) in the 7 MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017–2030.

<>High-grade Glioma (HGG) Detailed Epidemiology Segmentation
• The total incident population of High-grade Glioma in the 7 major markets was found to be 32,444 in 2017. In case of High-grade Glioma patients in the United States, the incident cases were estimated to be 16,295 in 2017.
• There are three main types of High-grade Gliomas that are considered in this report: Anaplastic Astrocytoma (WHO Grade III tumor), Glioblastoma (WHO Grade IV tumor) and Diffuse Midline Glioma (WHO Grade IV tumor), where the majority of cases were found to be of glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion.
• Incidence of Diffuse Midline Glioma with H3K27 Mutation has been considered in this report as well. The highest incidence of H3K27 mutants were found in pediatric population which was estimated to be 303 in 2017 in the United States. However, the incident population of H3K27 mutants in adult population was found to be 204 in 2017 in the United States.
• Japan accounted for 2,519 incident cases of High-grade Glioma in 2017, which is expected to increase in the forecast period 2020–2030.

Scope of the Report
• The report covers the descriptive overview of High-grade Glioma (HGG), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of High-grade Glioma (HGG).
• The report provides the segmentation of the disease epidemiology for the 7MM by Total Diagnosed Prevalent Population of High-grade Glioma (HGG) and Severity-based Diagnosed Prevalent Population of High-grade Glioma (HGG).

Report Highlights
• Eleven Year Forecast of High-grade Glioma (HGG)
• 7MM Coverage
• Total Diagnosed Prevalent Population of High-grade Glioma (HGG)
• The report contains Gender-specific prevalence of HGG in the 7MM, wherein males are found to suffer more as compared to females.
• Report also covers Incident Population of Diffuse Midline Glioma, including both adult and pediatric population of HGG.
• the analyst has also estimated Incident Population of Diffuse Midline Glioma With H3K27 Mutation, including both adult and pediatric population of HGG. It was found that H3K27 mutation is more prevalent in adult DMG patients than in pediatric DMG patients.
• The most commonly used chemotherapeutic drug for treating HGG in the United States is temozolomide (Temodar/Temodal; TMZ). It is generally used in combination with radiation therapy.

Key Questions Answered
• What is the disease risk, burden and unmet needs of High-grade Glioma (HGG)?
• What is the historical High-grade Glioma (HGG) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of High-grade Glioma (HGG) at the 7 MM level?
• What will be the growth opportunities across the 7 MM with respect to the patient population pertaining to High-grade Glioma (HGG)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of High-grade Glioma (HGG) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7 MM during the forecast period (2020–2030)?

Reasons to buy
The High-grade Glioma (HGG) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7 MM High-grade Glioma (HGG) market.
• Quantify patient share distribution in the 7 MM for High-grade Glioma (HGG).
• The High-grade Glioma (HGG) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The High-grade Glioma (HGG) epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

<>• Patient Segmentation
• Disease Risk and Burden

<>• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on